Precision BioSciences, Inc. (Nasdaq: DTIL) announced that it dosed the first patient in August in its Phase 1/2 FUNCTION-DMD clinical ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE